Razi Cov Pars / Razi Vaccine and Serum Research Institute - LARVOL DELTA

Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety. (PubMed, Heliyon) - "Considering rare side effects is essential in evaluating COVID-19 vaccines, especially those associated with ChAdOx1-S (AstraZeneca) and Ad26.COV2.S (Janssen), including blood clotting and idiopathic thrombocytopenia...Participants receiving the Razi-CoV-Pars booster after Sinopharm/BBIBP-CorV showed significantly higher antibody levels (Wuhan ∼ 3.25 times, Delta ∼4 times, Omicron ∼ 14 times) compared to those receiving Sinopharm's homologous vaccine...However, individuals receiving Sinopharm's booster after two doses showed a significant increase (4 cases) in D-Dimer levels. The Razi-CoV-Pars vaccine demonstrates a favorable safety profile and promising potential as an effective booster against current variants, particularly due to its significant protective titer against Omicron."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial. (PubMed, Vaccines (Basel)) - "We detected no serious adverse reactions or anaphylaxis and all adverse events resolved completely during the follow-up period and were similar in both groups. Intranasal RCP is safe, stimulates the respiratory mucosal immunity, and could be a booster on various COVID-19 vaccines and be effective against new virus variants."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial. (PubMed, Heliyon) - "The upper boundary of 99.1% confidence interval of HR = 0.91 (0.67-1.22) remained below the margin of non-inferiority in the randomized arm after observing the early stopping rules using O'Brien Fleming method. Our study showed that the RCP efficacy is non-inferior and its safety profile is comparable to the BBIBP."

Head-to-Head • Journal • P3 data • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial. (PubMed, BMC Med) - "BBIBP-CorV and RCP vaccines as booster doses are safe and provide a strong immune response that is more robust when the RCP vaccine is used. Heterologous vaccines are preferred as booster doses."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CD8 • IFNG • IL2 • TNFA

Phase II, Safety and immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 vaccine in adults aged 18-70 years; a randomized, double-blind clinical trial. (PubMed, J Pharm Sci) - "RCP vaccine is safe and creates strong and durable humoral and cellular immunity."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • IL6

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models. (PubMed, Front Immunol) - "Of the three tested vaccine regimens, the middle dose of the vaccine showed the best protective immune parameters. This vaccine with heterologous prime-boost vaccination method can be a good candidate to control the viral infection and its spread by stimulating central and mucosal immunity."

Journal • Preclinical • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases